COVID-19 Therapeutic Alert: Casirivimab and imdevimab for patients hospitalised due to COVID-19
The combination monoclonal antibody casirivimab plus imdevimab (Ronapreve®) should now be considered at a total dose of 2.4g in COVID positive antibody seronegative patients who have been hospitalised to manage the symptoms of COVID infection and who are either aged 50 and over, OR aged 12 to 49 AND considered immunocompromised.
Published